Lisata Therapeutics, Inc.
Lisata Therapeutics, Inc., a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in the United States. Founded in 2018, the company has rapidly established itself as a leader in developing innovative therapeutic solutions, particularly in the realm of oncology and rare diseases.
With a focus on advanced drug formulations and delivery systems, Lisata Therapeutics offers unique products that address unmet medical needs, setting them apart in a competitive market. The company’s commitment to research and development has led to significant milestones, including successful clinical trials and strategic partnerships that enhance its market position.
Lisata Therapeutics continues to drive advancements in pharmaceutical manufacturing, aiming to improve patient outcomes through its cutting-edge therapies and dedication to excellence in the healthcare sector.
-20 vs industry average
Lisata Therapeutics, Inc.’s score of 18 is lower than 26% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Lisata Therapeutics, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2025
Reported emissions
Scope 3 accounts for ••• of total emissions.
Lisata Therapeutics, Inc.'s reported carbon emissions
Lisata Therapeutics, Inc., a pharmaceutical preparation manufacturing company headquartered in the US, has reported its carbon emissions for 2022 and 2021. In 2022, the company's Scope 1 emissions were approximately 404,000 kg CO2e, and Scope 2 emissions were about 282,600 kg CO2e, resulting in a combined total of approximately 686,600 kg CO2e. Scope 3 emissions data was not disclosed for this year, with purchased goods and services identified as a missing data point. For 2021, Lisata Therapeutics reported Scope 1 emissions of approximately 533,000,000 kg CO2e. Data for Scope 2 and Scope 3 emissions were not available for 2021, with purchased goods and services noted as a missing Scope 3 data point. Lisata Therapeutics, Inc. has not publicly disclosed specific carbon reduction targets or commitments, nor is there information on participation in initiatives like the Science Based Targets initiative (SBTi). The company's emissions data is not cascaded from a parent organisation, with its own reporting for Scope 1 and Scope 2 emissions.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Lisata Therapeutics, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Lisata Therapeutics, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Lisata Therapeutics, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project